{
    "clinical_study": {
        "@rank": "168312", 
        "acronym": "RUFPTPS", 
        "arm_group": [
            {
                "arm_group_label": "Rufinamide", 
                "arm_group_type": "Experimental", 
                "description": "- oral Rufinamide administration as ad-on to Oxycodone"
            }, 
            {
                "arm_group_label": "Manitol", 
                "arm_group_type": "Placebo Comparator", 
                "description": "- oral Placebo administration - as ad-on to Oxycodone"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test if rufinamide has an effect on chronic neuropathic pain\n      in patients with a post thoracotomy pain syndrome."
        }, 
        "brief_title": "Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral Nerve Injuries", 
            "Pain"
        ], 
        "condition_browse": {
            "mesh_term": "Wounds and Injuries"
        }, 
        "detailed_description": {
            "textblock": "Patients with chronic neuropathic pain after thoracic surgery will be evaluated and treated\n      with oxycodone. Patients with a stable analgesic regimen, not reaching a good pain relief\n      will be randomized to receive Rufinamide (Inovelon)vs. Placebo as an ad-on treatment to\n      oxycodone. Neurophysiological and clinical data will be monitored."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria, Run-In Phase:\n\n          -  Age: 18-75 years\n\n          -  Weight: 50 - 100kg\n\n          -  Height: 155 - 195cm\n\n          -  Sufficient command of German language\n\n          -  Patient after thoracotomy\n\n          -  Pain duration of more than 6 month.\n\n          -  Diagnosis of Neuropathic Pain (DN4 questionnaire)\n\n          -  Average baseline mean last week pain intensity =5 on NRS (numerical rating scale)\n\n          -  Signed and dated informed consent\n\n        Inclusion criteria, Treatment Phase:\n\n          -  Stable analgesic regimen for at least 7 days prior to randomisation\n\n          -  Patients not reaching a NRS = 3 (numeric rating scale) with the baseline individually\n             dose adjusted treatment (oxycodone).\n\n        Exclusion criteria:\n\n          -  Contraindications to the class of drugs under study, e.g. (rufinamide, oxycodone)\n             known hypersensitivity or allergy this class of drugs\n\n          -  Hypersensitivity to triazole derivates - antifungal drugs including: fluconazole\n             (e.g. Diflucan\u00ae), posaconazole (Noxafil\u00ae), itraconazole (Sporanox\u00ae), voriconazole\n             (Vfend\u00ae)\n\n          -  Lactose intolerance, galactosemia or galactokinase deficiency, glucose-galactose\n             malabsorption\n\n          -  Use of topical analgesics, or nerve block of the affected or adjacent dermatomes\n             (less than to 2 weeks prior to the therapy onset visit or during the study period)\n\n          -  Women who are pregnant or breast feeding; intention to become pregnant during the\n             course of the study, lack of safe contraception, defined as: female subjects of\n             childbearing potential, not using and not willing to continue using a medically\n             reliable method of contraception for the entire study duration, such as oral,\n             injectable, or implantable contraceptives, or intrauterine contraceptive devices, or\n             who are not willing or able to use any other second (additional) considered\n             sufficiently reliable by the investigator in individual cases. Female subjects who\n             are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years\n             are not considered as being of child bearing potential\n\n          -  Other clinically significant concomitant disease states (e.g., renal failure, hepatic\n             dysfunction, severe cardiovascular disease, etc)\n\n          -  Creatinine clearance = 30 ml/min (estimated from serum creatinine using the Cockcroft\n             - Gault formula) were excluded\n\n          -  Known drug (opiate or other) or alcohol abuse\n\n          -  Contraindication to the use of oxycodone\n\n          -  Inability to follow the procedures of the study, e.g. due to language problems,\n             psychological disorders, dementia, etc. of the subject\n\n          -  Participation in another study with investigational drugs within the 30 days\n             preceding and during the present study\n\n          -  Enrollment of the investigators, his/her family members, employees and other\n             dependent persons\n\n          -  Known neurological disease with peripheral manifestations including neuropathy\n             associated with disease such as diabetes\n\n          -  Known sensory changes from other medical conditions (e.g. infections affecting the\n             investigation areas, post-herpetic neuralgia)\n\n          -  Epilepsy\n\n          -  Abnormal electrocardiogram (especially Familial Short QT syndrome)\n\n          -  Patient having another pain condition with greater pain intensity\n\n          -  Repeated thoracic surgeries\n\n          -  Pneumonectomy or chest wall resection\n\n          -  Bilateral thoracic surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095899", 
            "org_study_id": "2013-253"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rufinamide", 
                "Manitol"
            ], 
            "description": "2x200mg up to max 2x800mg a day Titration over 20days", 
            "intervention_name": "Rufinamide", 
            "intervention_type": "Drug", 
            "other_name": "Inovelon"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Thoracic Surgical Procedures", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "contact": {
                "email": "Konrad.Maurer@usz.ch", 
                "last_name": "Konrad Maurer, MD", 
                "phone": "+41 44 255 93 79"
            }, 
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich, Institut of Anaesthesiology"
            }, 
            "investigator": {
                "last_name": "Lucian M Macrea, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome. A Prospective, Randomized, Double-blind, Placebo Controlled, Monocenter Study.", 
        "overall_contact": {
            "email": "lucian.macrea@usz.ch", 
            "last_name": "Lucian M. Macrea, MD"
        }, 
        "overall_contact_backup": {
            "email": "konrad.maurer@usz.ch", 
            "last_name": "Konrad Maurer, MD"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Institut of Anaesthesiology", 
            "last_name": "Konrad Maurer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary variable to test is the area of punctuate hyperalgesia after topical capsaicin application in patients treated with rufinamide versus placebo.", 
            "measure": "Area of punctuate hyperalgesia  immediately after topical capsaicin.", 
            "safety_issue": "No", 
            "time_frame": "2h after capsaicin removal"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}